Summary: DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 5 or 6 Patients, With or Without Compensated Cirrhosis
Recommended regimen for:
DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 5 or 6 Patients, With or Without Compensated Cirrhosisa 
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)
|
12 weeks
|
IIa, B
|
|
a For decompensated cirrhosis, please refer to the appropriate section.
|
